Table 1.
Baseline characteristics
| Group 1: HER2 mutation (n = 16) | Group 2: HER2 amplification (n = 16) | Overall (n = 32) | ||||
|---|---|---|---|---|---|---|
| Characteristic | No. | % | No. | % | No. | % |
| Median age, years (range) | 64 (38–73) | 64 (35–83) | 64 (35–83) | |||
| Male sex | 5 | 31% | 10 | 63% | 15 | 47% |
| ECOG status | ||||||
| 0 | 8 | 50% | 12 | 75% | 20 | 63% |
| 1 | 7 | 43% | 3 | 19% | 10 | 31% |
| 2 | 1 | 6% | 1 | 6% | 2 | 6% |
| Lines of prior systemic treatment, median (range) | 2 (0–7) | 2 (0–4) | 2 (0–7) | |||
| Cancer origin | ||||||
| Lung | 11 | 69% | 1 | 6% | 12 | 38% |
| Salivary gland | 1 | 6% | 4 | 25% | 5 | 16% |
| Colorectal | 5 | 31% | 5 | 16% | ||
| Ovary | 3 | 19% | 3 | 9% | ||
| Gallbladder | 2 | 13% | 2 | 6% | ||
| Uterus | 1 | 6% | 1 | 6% | 2 | 6% |
| Cervix | 1 | 6% | 1 | 3% | ||
| Bladder | 1 | 6% | 1 | 3% | ||
| Pancreas | 1 | 6% | 1 | 3% | ||